Metacrine, Inc.

Metacrine, Inc. (MTCR) priced its initial public offering on Sep 16, 2020 at $13.00 per share, raising $85M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $337M. Jefferies was lead-left underwriter, joined by Evercore ISI, RBC Capital Markets and Canaccord Genuity. Cooley advised the company and Latham & Watkins advised the underwriters.

Metacrine, Inc. is a clinical-stage biopharmaceutical company developing therapies for liver and gastrointestinal diseases. Its most advanced program targets the farnesoid X receptor, and it has selected two oral candidates, MET409 and MET642, from a library of over 2,500 FXR compounds.

Status

IPO

Ticker

MTCR

Exchange

Nasdaq Global Market

Priced

Sep 16, 2020

IPO price

$13.00

Raised

$85M

Market cap at IPO price

$337M

First filed

Aug 24, 2020

Underwriters

Jefferies, Evercore ISI, RBC Capital Markets and Canaccord Genuity

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.